Current Cardiology Reports

, Volume 3, Issue 5, pp 416–423

Pathophysiology and treatment of the dyslipidemia of insulin resistance

Authors

  • Gregory Cohn
    • Cleveland Clinic Florida
  • Gerardo Valdes
  • David M. Capuzzi
Article

DOI: 10.1007/s11886-001-0059-0

Cite this article as:
Cohn, G., Valdes, G. & Capuzzi, D.M. Curr Cardiol Rep (2001) 3: 416. doi:10.1007/s11886-001-0059-0

Abstract

Insulin resistance, and the compensatory hyperinsulinemia that results, has been linked to a host of defects including glucose intolerance, diabetes, hypertension, dyslipidemia, endothelial dysfunction, impaired fibrinolysis, and subclinical inflammation. Patients with this metabolic syndrome have a markedly increased risk for the development of atherothrombotic cardiovascular disease. The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol. Management of this dyslipidemia typically involves a dual approach. Lifestyle modification is an essential component of any successful treatment plan, but alone is usually insufficient to correct these lipoprotein abnormalities. Medications that diminish insulin resistance and directly alter lipoproteins are also necessary in the majority of cases. Combinations of therapeutic agents are often required to optimize attainment of treatment goals.

Copyright information

© Current Science Inc 2001